Drug intelligence / Profile preview

Xiaoying Paste

Development stage: Unknown
Lead developer: Shanghai Municipal Hospital of Traditional Chinese Medicine
Administration: Topical

Overview

Xiaoying Paste (消瘿贴) is a topical Traditional Chinese Medicine (TCM) formulation developed by the Shanghai Traditional Chinese Medicine Hospital specifically for the treatment of Hashimoto's thyroiditis. The paste is applied externally to the skin overlying the thyroid gland. According to TCM principles, the therapy works by promoting the local circulation of 'Qi' and 'blood,' softening hardness, and resolving the phlegm-stagnation that characterizes goiter (瘿病). In clinical observation studies, it is investigated for its ability to reduce thyroid volume and lower levels of thyroid autoantibodies, such as thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies (TgAb), thereby addressing the underlying autoimmune inflammation of the thyroid gland.

Other names: 消瘿贴Xiaoying Tie

Beyond the preview

Go deeper on Xiaoying Paste.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiaoying Paste.

Explore the full profile